Income Statement (TTM)
Mankind Pharma Limited Income Statement shows changes in income and expenses over a period of time. Income Statement data includes Sales and Revenue, Gross Profit, Research and Development (R&D), Selling, General and Administrative Expense (SG&A), Operating Income, Income Tax Expense, Interest Expense, Non-Operating Income, Earnings per Share (EPS), and Shares Outstanding.
All numbers are times 1,000,000 except per share units.
|
2021 03-31 |
2022 03-31 |
2022 12-31 |
2023 03-31 |
2023 06-30 |
2023 09-30 |
2023 12-31 |
2024 03-31 |
2024 06-30 |
2024 09-30 |
2024 12-31 |
2025 03-31 |
2025 06-30 |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 62,144 | 77,816 | 84,225 | 87,494 | 91,481 | 94,303 | 99,463 | 103,348 | 106,496 | 110,180 | 116,410 | 122,074 | 129,099 |
| Change (%) | 25.22 | 8.24 | 3.88 | 4.56 | 3.09 | 5.47 | 3.91 | 3.05 | 3.46 | 5.65 | 4.87 | 5.75 | |
| % of Revenue | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 |
| Cost Of Sales | 18,471 | 24,879 | 28,808 | 30,031 | 29,783 | 30,864 | 32,356 | 33,056 | 33,133 | 33,633 | 34,710 | 36,596 | 39,037 |
| Change (%) | 34.69 | 15.79 | 4.25 | -0.83 | 3.63 | 4.83 | 2.16 | 0.23 | 1.51 | 3.20 | 5.43 | 6.67 | |
| % of Revenue | 29.72 | 31.97 | 34.20 | 34.32 | 32.56 | 32.73 | 32.53 | 31.98 | 31.11 | 30.53 | 29.82 | 29.98 | 30.24 |
| Gross Operating Profit | 43,673 | 52,937 | 55,417 | 57,463 | 61,697 | 63,439 | 67,108 | 71,251 | 73,363 | 76,547 | 81,701 | 85,479 | 90,062 |
| Change (%) | 21.21 | 4.69 | 3.69 | 7.37 | 2.82 | 5.78 | 6.17 | 2.96 | 4.34 | 6.73 | 4.62 | 5.36 | |
| % of Revenue | 70.28 | 68.03 | 65.80 | 65.68 | 67.44 | 67.27 | 67.47 | 68.94 | 68.89 | 69.47 | 70.18 | 70.02 | 69.76 |
| SG&A | 18,195 | 20,934 | 22,717 | 23,126 | 20,174 | 24,863 | 25,832 | 28,830 | 29,827 | 30,572 | 31,985 | 34,734 | 36,271 |
| Change (%) | 15.06 | 8.52 | 1.80 | -12.76 | 23.25 | 3.90 | 11.61 | 3.46 | 2.50 | 4.62 | 8.59 | 4.43 | |
| % of Revenue | 29.28 | 26.90 | 26.97 | 26.43 | 22.05 | 26.37 | 25.97 | 27.90 | 28.01 | 27.75 | 27.48 | 28.45 | 28.10 |
| R&D | |||||||||||||
| Change (%) | |||||||||||||
| % of Revenue | |||||||||||||
| OpEx | 46,241 | 59,493 | 68,992 | 71,612 | 73,791 | 75,400 | 79,502 | 81,980 | 84,912 | 86,160 | 91,837 | 98,003 | 104,436 |
| Change (%) | 28.66 | 15.97 | 3.80 | 3.04 | 2.18 | 5.44 | 3.12 | 3.58 | 1.47 | 6.59 | 6.71 | 6.56 | |
| % of Revenue | 74.41 | 76.45 | 81.91 | 81.85 | 80.66 | 79.96 | 79.93 | 79.32 | 79.73 | 78.20 | 78.89 | 80.28 | 80.90 |
| Operating Income | 15,903 | 18,322 | 15,233 | 15,883 | 17,690 | 18,903 | 19,961 | 21,502 | 21,584 | 24,020 | 24,573 | 24,071 | 24,663 |
| Change (%) | 15.21 | -16.86 | 4.26 | 11.38 | 6.86 | 5.60 | 7.72 | 0.38 | 11.29 | 2.31 | -2.04 | 2.46 | |
| % of Revenue | 25.59 | 23.55 | 18.09 | 18.15 | 19.34 | 20.04 | 20.07 | 20.81 | 20.27 | 21.80 | 21.11 | 19.72 | 19.10 |
| Interest Expense | -193 | -558 | -485 | -403 | -346 | -287 | -251 | -278 | -332 | -316 | -2,434 | -4,209 | -5,807 |
| Change (%) | 188.97 | -13.02 | -16.99 | -14.17 | -17.02 | -12.46 | 10.80 | 19.23 | -4.58 | 669.02 | 72.93 | 37.97 | |
| % of Revenue | -0.31 | -0.72 | -0.58 | -0.46 | -0.38 | -0.30 | -0.25 | -0.27 | -0.31 | -0.29 | -2.09 | -3.45 | -4.50 |
| Net Income | 12,654 | 14,335 | 11,865 | 12,819 | 14,762 | 15,575 | 17,271 | 19,129 | 19,625 | 21,150 | 20,414 | 19,910 | 18,928 |
| Change (%) | 13.28 | -17.23 | 8.04 | 15.16 | 5.51 | 10.89 | 10.76 | 2.59 | 7.77 | -3.48 | -2.47 | -4.93 | |
| % of Revenue | 20.36 | 18.42 | 14.09 | 14.65 | 16.14 | 16.52 | 17.36 | 18.51 | 18.43 | 19.20 | 17.54 | 16.31 | 14.66 |
Source: Capital IQ
